Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Endocrinology

Understanding Your Diagnosis: 46,XX GD vs. Similar Conditions

At a Glance

46,XX gonadal dysgenesis (GD) is often confused with MRKH, Turner Syndrome, or POI. Unlike MRKH, people with GD have a uterus that is very small due to low estrogen. This uterus can grow once hormone replacement therapy begins. A 46,XX karyotype and high FSH levels confirm the diagnosis.

When you first receive a diagnosis of 46,XX gonadal dysgenesis (GD), it is common to feel confused by the many medical terms and similar-sounding conditions. Because several conditions cause a person to miss their period or have low hormone levels, doctors must use specific tests to tell them apart.

Understanding these differences can help clarify your diagnosis and what it means for your body’s development.

The “Invisible” Uterus: GD vs. MRKH

One of the most common points of confusion is between 46,XX gonadal dysgenesis and MRKH syndrome (Mayer-Rokitansky-Küster-Hauser). Both can cause primary amenorrhea (not starting a period), but for different biological reasons [1][2].

  • MRKH (Uterine Agenesis): In MRKH, a person is born without a uterus or the upper part of the vagina, but their ovaries work perfectly [1][2]. Their body produces normal levels of estrogen, so they typically go through puberty (developing breasts and hair) but do not have periods [2][3].
  • 46,XX GD (Uterine Hypoplasia): In GD, the person is born with a uterus, but because the ovaries are not making estrogen, the uterus stays “infantile”—tiny and underdeveloped [4][5].

Why misdiagnosis happens: On an initial ultrasound, a tiny, infantile uterus can be so small that it is invisible to the radiologist, leading them to mistakenly suggest it is missing (MRKH) [4][6]. However, once a person with GD starts Hormone Replacement Therapy (HRT), the uterus often begins to grow and becomes clearly visible on imaging [4][6].

Karyotype and Appearance: GD vs. Turner Syndrome

Turner Syndrome is perhaps the most well-known form of gonadal dysgenesis, but it is distinct from 46,XX GD.

  • Turner Syndrome: This is caused by a missing or altered X chromosome (typically a 45,X karyotype) [7]. People with Turner Syndrome often have specific physical traits, such as short stature or a wider neck [8][1].
  • 46,XX GD (Pure Gonadal Dysgenesis): People with this condition have a typical female 46,XX karyotype in every cell [1][9]. Because they have the typical chromosomal blueprint, they usually do not have the physical traits associated with Turner Syndrome and are typically of average height [8][4].

The Timing of Ovarian Function: GD vs. POI

Primary Ovarian Insufficiency (POI) is an umbrella term for any time the ovaries stop working before age 40 [10].

Feature 46,XX Gonadal Dysgenesis Typical POI
Puberty Usually does not start naturally [1][8]. May start naturally and then stop [9].
Ovary Appearance Often seen as “streak ovaries” (fibrous tissue) [9][11]. May show small follicles or appear “early-aged” [12].
Cause Primarily a developmental or genetic “error” from birth [13]. Can be genetic, autoimmune, or caused by medical treatments [12][14].

Summary of Differences

The key to distinguishing these conditions lies in the hormone profile. In 46,XX GD, doctors find hypergonadotropic hypogonadism:

  1. Low Estrogen: Because the ovaries didn’t develop [9].
  2. High FSH/LH: Because the brain is sending high-level signals to try and wake the ovaries up [9][11].

If a person has a typical female karyotype (46,XX), high FSH levels, and a tiny (but present) uterus, the diagnosis is confirmed as 46,XX gonadal dysgenesis [1][9]. This clarity is helpful because it confirms that the uterus is ready to grow and function once it receives the estrogen it needs [4][6].

Common questions in this guide

Why might an ultrasound show a missing uterus when I actually have 46,XX GD?
In 46,XX gonadal dysgenesis, the uterus is present but stays very small due to a lack of estrogen. Because it is infantile, it can be hard to see on an initial ultrasound, leading doctors to mistakenly suspect conditions like MRKH where the uterus is missing.
Will my tiny uterus grow to a normal size with 46,XX GD?
Yes, once you start Hormone Replacement Therapy (HRT), the estrogen helps your underdeveloped uterus grow. Follow-up imaging typically shows the uterus becoming clearly visible as it develops.
What is the difference between 46,XX GD and Turner Syndrome?
While both conditions affect ovary development, Turner Syndrome is caused by a missing or altered X chromosome and is associated with physical traits like short stature. People with 46,XX GD have a typical female chromosomal pattern and are usually of average height.
How do doctors confirm a diagnosis of 46,XX gonadal dysgenesis?
Doctors confirm the diagnosis by looking at your hormone profile, chromosomes, and pelvic imaging. Finding a typical 46,XX karyotype, an infantile but present uterus, low estrogen, and high FSH and LH levels helps confirm 46,XX GD over other conditions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How can we be certain my diagnosis isn't MRKH if the first ultrasound didn't show a uterus?
  2. 2.Can we schedule a follow-up ultrasound after I have been on estrogen therapy for a few months to check for uterine growth?
  3. 3.Does my karyotype show a full 46,XX pattern in every cell, or is there any sign of mosaicism?
  4. 4.Based on my hormone levels, is this considered 'pure' gonadal dysgenesis or a form of POI?
  5. 5.If my uterus is present but small, what are the chances it will reach a typical size with hormone therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    A rare case of 46,XX gonadal dysgenesis, Mayer-Rokitansky-Kuster-Hauser syndrome, pituitary and thyroid hypoplasia.

    Ambachew R, Gulilat A, Aberra T, et al.

    Endocrinology, diabetes & metabolism case reports 2022; (2022()).

    PMID: 35142292
  2. 2

    Unveiling the Unknown: Nicaragua's First Recorded Case of Mayer-Rokitansky-Küster-Hauser Syndrome.

    Garcia MES, Rivera A, Vargas Salgado CM, et al.

    Cureus 2024; (16(11)):e72895 doi:10.7759/cureus.72895.

    PMID: 39624529
  3. 3

    Mayer-Rokitansky-Kuster-Hauser syndrome and stress urinary incontinence.

    Aniuliene R, Aniulis P

    European journal of obstetrics, gynecology, and reproductive biology 2015; (194()):233-5.

    PMID: 26454229
  4. 4

    Misdiagnosis of Mullerian agenesis in a patient with 46, XX gonadal dysgenesis: a missed opportunity for prevention of osteoporosis.

    Thewjitcharoen Y, Veerasomboonsin V, Nakasatien S, et al.

    Endocrinology, diabetes & metabolism case reports 2019; (2019()).

    PMID: 31809259
  5. 5

    Unanticipated diagnosis of Swyer syndrome: a case report.

    Giri KP, Thapa S, Rawat R, Rouniyar S

    Annals of medicine and surgery (2012) 2024; (86(10)):6293-6299 doi:10.1097/MS9.0000000000002535.

    PMID: 39359820
  6. 6

    A critical assessment of case reports describing absent uterus in subjects with oestrogen deficiency.

    Berglund A, Burt E, Cameron-Pimblett A, et al.

    Clinical endocrinology 2019; (90(6)):822-826 doi:10.1111/cen.13963.

    PMID: 30820975
  7. 7

    Balanced Reciprocal Translocation t(X;1) in a Girl with Tall Stature and Primary Amenorrhea.

    Razavi Z, Momtaz HE

    Iranian journal of medical sciences 2017; (42(2)):210-214.

    PMID: 28360449
  8. 8

    Clinical features and management of 33 patients with 46,XX pure gonadal dysgenesis.

    Huang H, Wang CQ, Tian QJ

    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2016; (32(12)):995-998 doi:10.1080/09513590.2016.1190820.

    PMID: 27250571
  9. 9

    Misdiagnosis of associated mullerian agenesis in a female with 46, XX gonadal dysgenesis: a case report and review of literature.

    Opdecam L, Barudy Vasquez J, Camerlinck M, Makar A

    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 2021; (41(7)):1164-1165 doi:10.1080/01443615.2020.1798908.

    PMID: 33054466
  10. 10

    Molecular Aspects and Clinical Relevance of GDF9 and BMP15 in Ovarian Function.

    Belli M, Shimasaki S

    Vitamins and hormones 2018; (107()):317-348 doi:10.1016/bs.vh.2017.12.003.

    PMID: 29544636
  11. 11

    Coexistence of Gonadal Dysgenesis and Mullerian Agenesis in a Female with 46 XX Karyotype: A Case Report.

    Jha SK, Manandhar R, Shrivastava VR

    JNMA; journal of the Nepal Medical Association 2019; (57(216)):119-122.

    PMID: 31477946
  12. 12

    A homozygous truncating variant in GDF9 in siblings with primary ovarian insufficiency.

    Verma KP, Thompson B, Wolfe J, et al.

    Journal of assisted reproduction and genetics 2021; (38(6)):1539-1543 doi:10.1007/s10815-021-02144-x.

    PMID: 33797006
  13. 13

    Identification of novel variants and candidate genes in women with 46,XX complete gonadal dysgenesis.

    Ding L, Deng S, Zhang P, et al.

    Reproductive biology and endocrinology : RB&E 2024; (22(1)):140 doi:10.1186/s12958-024-01309-4.

    PMID: 39529088
  14. 14

    Variants in Homologous Recombination Genes EXO1 and RAD51 Related with Premature Ovarian Insufficiency.

    Luo W, Guo T, Li G, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(10)) doi:10.1210/clinem/dgaa505.

    PMID: 32772095

This page provides educational information on diagnosing 46,XX gonadal dysgenesis and how it differs from similar conditions. Always consult your endocrinologist or gynecologist for a formal diagnosis and personalized treatment plan.

Get notified when new evidence is published on 46,XX gonadal dysgenesis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.